{"nct_id":"NCT05664243","title":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2024-10","start_date":"2023-09-08","start_date_type":"ACTUAL","primary_completion_date":"2025-12","primary_completion_date_type":"ESTIMATED","completion_date":"2025-12","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["INAB"]}